|
|
 |
|
Viewing report
|
|
|
|
Rheumatoid Arthritis Drug Discoveries: What The Future Holds
Espicom Business Intelligence Ltd, March 2008, Pages: 250
With significant unmet clinical need and the progressive introduction of higher value and effective biopharmaceuticals, the rheumatoid arthritis market is expected to more than double in value to US$27 billion by 2015. This new management report provides a complete examination of the RA market and its prospects in the medium term.
Prevalence and incidence – where in the world?
Rheumatoid arthritis is the most common chronic inflammatory joint disease. The incidence of RA among white populations is approximately 3 people per 10,000 or 0.03 per cent per annum worldwide, although this can vary markedly between different regions. RA is rare in rural and less developed parts of the world; indeed, one large study in Nigeria failed to find a single case of RA. It is also known to be rare in China and Indonesia, and the incidence is very low in Japan, suggesting urbanised and westernised lifestyles may have a key role in the onset of the disease.
RA is relatively uncommon in patients aged less than 15 years, with incidence increasing up to the age of 70 years before tailing off. The commonest age of onset is between 40 and 50 years of age. Overall, the prevalence in North America and the European Union is expected to increase until at least 2010, due to the aging population. At the same time, prevalence in rural countries is expected to continue to increase.
A rising market
We estimate the global rheumatoid arthritis market was worth approximately US$11.6 billion in 2007, accounting for 1.7 per cent of global pharmaceutical sales (which were US$691.2 billion in 2007). Global sales include the non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, traditional disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate, (MTX), and the biologic therapies. The biologics account for the greatest proportion of sales, although the majority of patients are still treated with the traditional DMARDs.
By 2015, we expect the global RA market to generate sales of around US$27 billion due to the growth in sales of existing and new biologic therapies, which will remain as the main growth drivers. The new oral therapies will begin to make a further impact on market growth from 2011. The uptake of these more effective newer agents will lead to a decline in sales of established treatments to 2015.
Price pressure and safety: blocks to growth?
Against these possibilities for future market growth, there looms the spectre of the financial strain placed on healthcare systems by the prescription of highly-priced biologics, which may limit their use. In the treatment of RA, the cost of the new biologics is considerably higher than the cost of the traditional treatments. In addition, unexpected safety issues may impact market growth of the RA market as a whole. For instance, the withdrawal of Merck & Co's Vioxx and Pfizer's Bextra has seen a slowdown in the uptake of Cox-2 inhibitors in the treatment of the signs and symptoms of RA.
Questions answered
-Who will be the leading players in the RA market in 2015 and what products and approaches will be influential?
-What advantages will the new generation of biopharmaceuticals have over existing treatments?
-How extensive is Pfizer’s development portfolio in RA?
-How important will combination therapy be in the RA sector?
-Enbrel, Remicade and Humira – who will win the battle for sales, and why?
Evaluation and forecasts for leading therapies and prospects include...
Customers who bought this item also bought
The Rheumatoid Arthritis Market - Competitive Landscape and Clinical Stage Analysis
Pipeline Insight: Disease Modification in Rheumatoid Arthritis - New drug targets compete in crowded market
Pipeline Insight: Disease Modification In Rheumatoid Arthritis - Competition For The Anti-TNF Failure Patient Population Increases
US market size for methotrexate and anti-TNF rheumatoid arthritis therapies by number of patients, with total rheumatoid arthritis population, number of people diagnosed, and number of RA suffers treated with pharmaceuticals
Rheumatoid Arthritis: Market Trends and R&D Insights
Stakeholder Insight: Rheumatoid Arthritis - Biologics Battle Up the Treatment Algorithm
Arthritis in the United States
Rheumatoid Arthritis Market Evaluation: A Survey of 50 Board-certified or Board-eligible Rheumatologists
Disease Modification in Rheumatoid Arthritis - The Biologics Boom
Disease and Therapy Review: Rheumatoid Arthritis
Therapeutic Clinical Intelligence - Rheumatoid Arthritis - 2009 Edition
Latin American Rheumatoid Arthritis Drugs Market
|
|
|
|
